Skip to main content

Table 2 Association between Recurrence Score results and disease outcomes

From: The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

  5-year Kaplan-Meier risk estimate (%) and 95% CI by Recurrence Score group  
Risk Low (<  18) Intermediate (18-31) High (≥ 31) HR per 50 units* (95% CI)
DR 93.7 (89.4-96.3) 87.3 (81.0-91.6) 69.3 (61.5-75.8) 4.14 (2.67-6.43)
p <  0.001    p <  0.001§
DFS 90.8 (86.0-94.1) 84.9 (78.3-89.6) 64.6 (56.7-71.4) 3.28 (2.18-4.94)
p <  0.001    p <  0.001§
OS 99.0 (96.2-99.8) 95.6 (90.9-97.9) 85.6 (79.1-90.2) 5.0 (3.01-8.28)
p < 0.001    p < 0.001§
  1. DR distant recurrence, 95%CI 95% confidence interval, HR hazard ratio, DFS disease-free survival, OS overall survival
  2. *Recurrence Score was a continuous variable in a Cox proportional hazards regression model, with the HR adjusted for treatment and calculated relative to an increment of 50 units
  3. p-value from log-rank test for comparison of entire Kaplan-Meier plots among the three Recurrence Score groups
  4. §p-value from Wald test for significance of HR